An AI Model Classifies Risks of Early Relapse Post-CAR T Cell Therapy in a Multi-Center Real-World Population with DLBCL

医学 决策树 内科学 心理干预 人口 红细胞压积 肿瘤科 置信区间 机器学习 重症监护医学 计算机科学 环境卫生 精神科
作者
Michelle Wang,Krishna V. Komanduri,Debajyoti Datta,Ayan R. Patel,Barbee Whitaker,Artur Belov,B. A. Rubin,Rohit Vashist,Rosa Rodríguez-Monguió,Pelin Cinar,Steven A. Anderson,Atul J. Butte
出处
期刊:Blood Advances [Elsevier BV]
标识
DOI:10.1182/bloodadvances.2025016375
摘要

Accumulating real-world (RW) evidence of axi-cel has demonstrated comparable performance to the pivotal trials. However, nearly 57% of patients eventually experience relapse, with most requiring additional therapies. Being able to identify patients with risk of early relapse enables clinicians to consider additional interventions to further extend survival outcomes. This study aimed to first comprehensively evaluate the RW performance of axi-cel in the multi-center University of California (UC) Health Systems using automated computational approaches. Secondly, we developed a decision tree machine learning (ML) model to identify patients with risks of early relapse within six months. 416 adult patients with DLBCL receiving axi-cel between 2017-2024 were included in the study. The median PFS, and OS were 10.1, and 54.4 months; the 18-month PFS and OS rates were 41.6 and 65.5%, respectively. Severe CRS and ICANS were observed in 18.8 and 32.5% of patients, respectively. The decision tree ML model, relying on age and six routinely measured laboratory tests (LDH, CRP, ferritin, hematocrit, platelet count, and PT), achieved a high AUROC score of 0.82. The decision curve analysis indicated positive net benefit of the model across a broad range of decision thresholds (0-0.7), indicating potential clinical utility in diverse scenarios. This study further confirmed the RW performance of axi-cel in diverse populations. Our ML model represented a novel approach to identify patients that may benefit from additional interventions to further extend survival outcomes. Following prospective confirmation study, our model and decision tree approach may support clinical decision making in patients with high-risk DLBCL.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
ayayaya发布了新的文献求助10
1秒前
唐唐发布了新的文献求助10
1秒前
乐观菠萝发布了新的文献求助10
1秒前
作业本的应助被MM采纳,获得10
1秒前
田様的应助被龙金兴采纳,获得10
2秒前
3秒前
3秒前
4秒前
CipherSage的应助被renn采纳,获得10
4秒前
zqy发布了新的文献求助10
5秒前
生动的面包完成签到,获得积分10
5秒前
honey发布了新的文献求助10
7秒前
凯旋888发布了新的文献求助10
7秒前
小二郎的应助被久处采纳,获得30
7秒前
7秒前
kkk发布了新的文献求助10
8秒前
乐超多完成签到,获得积分10
10秒前
10秒前
10秒前
孤独口红完成签到,获得积分10
11秒前
哈哈哈完成签到,获得积分10
11秒前
科研通AI6.3的应助被乐观荔枝采纳,获得10
11秒前
12秒前
奋斗的海豚完成签到 ,获得积分10
12秒前
Jasper的应助被陈陈陈采纳,获得10
13秒前
13秒前
隐形曼青的应助被111采纳,获得10
14秒前
WAO发布了新的文献求助10
16秒前
张豪完成签到,获得积分10
17秒前
18秒前
19秒前
大熊发布了新的文献求助10
19秒前
Jasper的应助被空中马铃薯采纳,获得10
20秒前
英姑的应助被wenhan采纳,获得10
20秒前
SciGPT的应助被唐唐采纳,获得10
21秒前
Lucas的应助被浮生采纳,获得10
21秒前
陈陈陈完成签到,获得积分10
21秒前
856关闭了856的文献求助
21秒前
大橘为重完成签到,获得积分10
22秒前
BeHappy完成签到,获得积分10
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184061
求助须知:如何正确求助?哪些是违规求助? 9573151
关于积分的说明 21829878
捐赠科研通 7781058
什么是DOI,文献DOI怎么找? 3434216
关于科研通互助平台的介绍 2558337
邀请新用户注册赠送积分活动 2480674